SecBot SecBot

CRVS

Corvus Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001626971 Biotech & Drug Discovery
$10.60 −0.04 (−0.38%)
Nov 16 4:00 PM ET · prev $10.64
Market cap
$895.8M
Small cap
Median target
$30.00
+183% · range $27.00–42.00
1 year
+19.0%
from $8.91 · Nov 17
30 days
+9.8%
from $9.65
52-week range
$6.50–25.52
−58% from high · low Jan 13
Avg volume 20D
993.5K
shares / day
Short interest
17.76M
≈21.1% of shares · −1.2%
Days to cover
18.9
at average volume
Insider net
+$384.2K
3 buyers · 0 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 4/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $384.2K at an average $11.59. No open-market sales. Price is 9% below their cost.

  • InstitutionsMIXED

    Q3 2026: 22 added (1 new), 15 trimmed or exited. Largest new: Fisher Asset Management $12.0M.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.228 → −$0.235 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.2% to 17.76M shares. 18.9 days to cover, ≈21.1% of shares.

  • TrendRANGE

    5% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
$12.0M
in new stakes
FundMoveSharesValue
STATE STREET CORPTRIM3,331,535$38.4M
Fisher Asset Management, LLCNEW1,040,606$12.0M
MORGAN STANLEYTRIM792,714$9.1M
Connor, Clark & Lunn Investment Management Ltd.ADD423,262$4.9M
VOYA INVESTMENT MANAGEMENT LLCADD196,918$2.3M
BARCLAYS PLCTRIM188,238$2.2M
SEI INVESTMENTS CODOUBLED181,515$2.1M
Squarepoint Ops LLCDOUBLED130,023$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Apr 2026
12-month targets · 6 analysts

Price is below the lowest target. Median implies +183%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Apr 17, 2026Goldman Sachs
INITIATE
INITIATEBuy
Mar 13, 2026Oppenheimer
REITERATE
REITERATEOutperform
Jan 22, 2026Jefferies
MAINTAIN
MAINTAINBuy
Jan 21, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Jan 21, 2026Barclays
MAINTAIN
MAINTAINOverweight
Jan 20, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$384.2K
bought · 3 insiders
$0
sold · 0 insiders
−8.6%
vs their $11.59 cost
DateInsiderTypeValue
Nov 13, 2026
Arcara Jeffrey
Chief Business Officer
Nov 13, 2026
BUY$5.2K
Nov 13, 2026
Arcara Jeffrey
Chief Business Officer
Nov 13, 2026
BUY$5.4K
Nov 12, 2026
Arcara Jeffrey
Chief Business Officer
Nov 12, 2026
BUY$5.5K
Nov 11, 2026
Arcara Jeffrey
Chief Business Officer
Nov 11, 2026
BUY$34.4K
Jun 11, 2026
Thompson Peter A.
Director
Jun 11, 2026
AWARD15,000 sh
Jun 11, 2026
Grais Linda
Director
Jun 11, 2026
AWARD15,000 sh
Jun 11, 2026
CLARK IAN T
Director
Jun 11, 2026
AWARD15,000 sh
Jun 11, 2026
Moore David Scott
Director
Jun 11, 2026
BUY$250.2K

Earnings setup

Estimates
−$0.23
EPS estimate, this quarter
−3%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.24–-$0.22-3.3%$0.00
Next Q-$0.27-$0.29–-$0.25-2.5%$0.00
Current FY-$0.80-$0.81–-$0.79-3.2%$0.00
Next FY-$1.10-$1.31–-$0.87-3.0%$1.6M

Short side

FINRA· Oct 30, 2026
17,759,451
shares short
-1.2%
vs prior settlement
18.9
days to cover
≈21.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Chief Business Officer Jeffrey Arcara purchased a total of $50K in CRVS shares over four open-market trades between…
INSIDER-BUY · Impact 3/10
Nov 13, 2026 Insider
Arcara Jeffrey bought 503 shares
Chief Business Officer @ $10.37 ($5.2K)
Nov 13, 2026 Insider
Arcara Jeffrey bought 500 shares
Chief Business Officer @ $10.71 ($5.4K)
Nov 12, 2026 Insider
Arcara Jeffrey bought 497 shares
Chief Business Officer @ $11.12 ($5.5K)
Nov 10, 2026 SEC
State Street Corp filed a Schedule 13G disclosing a passive 5%+ stake in Corvus Pharmaceuticals as of September 30…
SC 13G · Impact 3/10
Nov 9, 2026 Other
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Nov 5, 2026 SEC
Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M ($0.22 per share), wider than the $10.2M loss in Q3 2025…
PRESS-RELEASE · Impact 4/10
Nov 4, 2026 Press
Corvus Pharmaceuticals announced positive one-year safety and efficacy data from three ALPS patients in an NIAID-led…
Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

10 filings · 5 press releases · 2 bullish · 0 bearish · 8 neutral
All CRVS filing & press-release reports (15)